• OCTIMET Oncology NV secures over EUR 11 million to develop its highly selective MET kinase inhibitors

    Read more
  • Translational Accelerator

  • Dosing of First Patient with investigational agent OMO-1

    Read more
  • OCTIMET Oncology NV awarded €1.12 million grant from VLAIO

  • 1
  • 2
  • 3
  • 4


  • MET protein (green) in untreated H1993 lung cancer cells. Counterstained for DNA (blue).
  • Phospho MET protein (red) in untreated H1993 lung cancer cells. Counterstained for DNA (blue).
  • MET protein (green) in OMO treated H1993 lung cancer cells. Counterstained for DNA (blue).
  • Phospho MET protein (red) in OMO treated H1993 lung cancer cells. Counterstained for DNA (blue).

Images courtesy of Letizia Lanzetti - Membrane Trafficking Laboratory - Candiolo Cancer Institute- FPO, IRCCS - Torino (Italy)


Our team

  • Shelley Margetson, CEO

    Shelley Margetson has worked in various European biotech companies for close to 20 years. Prior to joining OCTIMET, she was the CEO of Gadeta, and previously CFO at Merus (NASDAQ: MRUS) where she played a pivotal role in their initial public listing on the Nasdaq in May 2016.
  • Tim Perera, PhD, CSO, Founder (Consultant)

    Tim has more than 25 years global pharma experience in drug development. Before setting up Octimet he was Global Discovery Leader Lung Disease Area at J&J. He has led 4 discovery projects that reached clinical stage.
  • Glen Clack, MD, FFPM, CMO (Consultant)

    Glen has 20 years experience in oncology drug development and translational medicine. Before joining Octimet has held the position of senior medical director at AstraZeneca.; He holds various honorary academic positions and is a member of the oncology innovative medicines group. He was involved in the clinical development of anastrozole, cediranib, vandetanib, saracatinib.
  • Annegret Van der Aa, PhD, COO

    Annegret has a broad R&D experience in small and mid-size biotech (Innogenetics, ActoGeniX and Galapagos) for more than 15 years after obtaining a PhD in Biomedical Sciences. She took up increasing responsibilities from managing a research group, compound strategic and operational leadership to building a clinical development/operations department which resulted in the transitioning of more than 10 preclinical candidates to clinical stage products in a variety of indications.
  • Marc Tjwa, MD, PhD, Medical Director

    Marc has a broad R&D experience at various stages of (oncological) drug discovery and development. Trained as Medical Doctor at KU Leuven (Belgium), Marc has 13 years of experience in fundamental research on angiogenesis and oncology while obtaining a PhD in Medicine at KU Leuven, and subsequently heading a new research laboratory in Frankfurt (Germany). Marc achieved more than 60 research publications. He then switched from academia to government administration by joining, for the past 4 years, the Clinical Trials (CT) section of the FAMHP (Belgium) where Marc was pivotal in the medical assessment of CT applications, in part by conceptualizing new assessment tools.
  • Eric Ciamporcero, PhD, Translational Scientist

    Eric has 10 years experience in oncology, resulting in more than 20 publications. Trained in Italy as a molecular biologist, he then worked in a translational research lab in Buffalo (NY), USA, where he conducted, among others, in vivo studies to assess efficacy of MET inhibitors. Eric joined Octimet after two years at J&J where, as postodoctoral scientist, he led target identification efforts, mainly through collaboration with CROs.
  • Ann Meulemans, PhD (Consultant)

    Ann has more than 25 years experience in product development and strategy. She brought more than 5 drugs in different indications from lead identification to POC in man.
  • Paolo Comoglio, MD, PhD, Scientific Advisor

    Paolo has more than 25 years experience with MET biology resulting in more than 300 publications. He is the Scientific Director of the Candiolo Cancer Institute – IRCCS in Turin, Italy. Prof Comoglio was one of the founding scientists of the MET biology field.
  • 1


  • V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies (www.v-bio.ventures).
  • FUND+ is an open-ended Fund for long term equity investment in innovative Life Sciences companies with a focus on Belgium (www.fundplus.be).
  • DROIA is a venture capital investor focusing exclusively on oncology therapeutics (www.droia.be).
  • Omnes Capital is a major player in private equity and infrastructure with €3 billion in assets under management (www.omnescapital.com).
  • VIB is a life sciences research institute, based in Flanders, Belgium. We perform basic research with a strong focus on translating scientific results into pharmaceutical, agricultural and industrial applications (http://www.vib.be).
  • Flanders Innovation & Entrepreneurship supports all types of innovators in Flanders (http://www.vlaio.be).
  • 1


OCTIMET is interested in discussing potential in- and out-licensing opportunities in translational oncology.

Please contact business development

JLINX Incubator



Turnhoutseweg 30, 2340 Beerse - Belgium

For general inquiries please contact

For business development inquiries please contact